Harvard spinout TScan Therapeutics has successfully listed on the Nasdaq Global Market.
TScan Therapeutics, the US-based cancer immunotherapy developer spun out of Harvard University, secured $100m in its initial public offering on Friday.
The company issued almost 6.7 million shares on the Nasdaq Global Market priced at $15 each, having set a range of $15 to $17 for 6.3 million shares. It is listed under the ticker symbol TCRX.
Founded in 2018, TScan is working on engineered T cell therapies aimed at treating patients with cancer. Its TargetScan discovery…
